tiprankstipranks
Trending News
More News >
Rezolute (RZLT)
NASDAQ:RZLT

Rezolute (RZLT) AI Stock Analysis

Compare
561 Followers

Top Page

RZ

Rezolute

(NASDAQ:RZLT)

53Neutral
Rezolute's overall stock score is impacted by its challenging financial performance, with persistent losses and operational inefficiencies. However, technical analysis shows moderate upward momentum, and positive corporate events, including significant funding and promising clinical trial progress, offer potential upside. Valuation remains weak with negative earnings, suggesting cautious optimism for the stock's future.
Positive Factors
Clinical Trials
The independent data monitoring committee recommends continuation of the sunRIZE trial without sample size adjustments, indicating confidence in the trial's design.
Financial Position
An equity financing with healthcare-focused institutional investors raised $90M in gross proceeds, which should extend the runway into mid-CY27.
Regulatory Approval
Rezolute has secured a second Breakthrough Therapy Designation for ersodetug, which reflects the FDA's recognition of its promising efficacy in treating tumor-induced hyperinsulinism.
Negative Factors
Financial Challenges
Risks include financial challenges, as the company is not generating revenue and has capital needs exceeding the current cash balance.
Market Uncertainties
The inclusion of the lower dose was to ensure flexibility in case any unexpected safety signals emerge, since the Ph3 study is enrolling more and younger patients than Ph2b, and with a longer treatment period.
Regulatory Concerns
The FDA lifted the age restriction for U.S. patients to be 12 years and older due to safety concerns.

Rezolute (RZLT) vs. S&P 500 (SPY)

Rezolute Business Overview & Revenue Model

Company DescriptionRezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
How the Company Makes MoneyRezolute generates revenue primarily through the development and potential commercialization of its proprietary drug candidates. The company aims to profit by advancing its products through clinical trials and obtaining regulatory approvals, leading to potential licensing agreements, partnerships, or direct sales. Revenues may also be supplemented by milestone payments or royalties from collaborations with larger pharmaceutical companies, which can provide financial support and distribution channels for their therapies. Currently, as a clinical-stage company, Rezolute may also rely on funding from investors, grants, and public offerings to support its research and development activities until its products reach the market.

Rezolute Financial Statement Overview

Summary
Rezolute faces significant financial challenges typical in biotechnology, with minimal revenue growth and substantial operational losses. The company maintains a strong equity position with low debt levels, but struggles with negative cash flow and profitability, reflecting operational inefficiencies.
Income Statement
30
Negative
Rezolute's revenue growth has been minimal with minor revenue in TTM after years of none, reflecting limited commercial success. The company has negative profitability margins with a net profit margin of -122639.66% and an EBIT margin of -94665.52% in TTM, indicating high operational losses relative to revenue. There is no visible trend of improvement in profitability as both EBIT and net income have consistently been negative.
Balance Sheet
55
Neutral
Rezolute shows a strong equity position with an equity ratio of 88.90% in TTM, indicating low financial leverage. The debt-to-equity ratio is minimal at 0.02, suggesting low debt levels relative to equity. However, the return on equity is negative at -71.44%, reflecting continued losses impacting shareholder returns.
Cash Flow
40
Negative
The company's free cash flow is negative, and the operating cash flow to net income ratio is 0.89, evidencing cash burn. However, financing activities have been a source of cash, indicating reliance on external funding. Free cash flow growth remains negative, reflecting operational inefficiencies.
Breakdown
Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
0.000.000.000.000.00
Gross Profit
-36.00K-382.00K-256.00K-303.00K-18.00K
EBIT
-70.42M-55.99M-41.84M-22.89M-20.52M
EBITDA
-68.42M-51.41M-41.83M-22.88M-20.32M
Net Income Common Stockholders
-68.46M-51.79M-38.78M-21.28M-20.33M
Balance SheetCash, Cash Equivalents and Short-Term Investments
126.87M101.90M150.41M41.05M9.96M
Total Assets
132.74M123.72M152.42M42.61M10.96M
Total Debt
2.23M2.48M188.00K14.42M410.00K
Net Debt
-68.17M-13.56M-150.22M-26.63M-9.54M
Total Liabilities
11.73M7.55M2.95M16.51M3.60M
Stockholders Equity
121.00M116.17M149.47M26.10M7.37M
Cash FlowFree Cash Flow
-57.37M-44.63M-39.62M-20.44M-24.17M
Operating Cash Flow
-57.37M-44.48M-39.62M-20.44M-24.17M
Investing Cash Flow
48.70M-101.46M0.000.000.00
Financing Cash Flow
63.03M11.57M148.98M51.53M22.55M

Rezolute Technical Analysis

Technical Analysis Sentiment
Positive
Last Price4.12
Price Trends
50DMA
3.40
Positive
100DMA
4.13
Negative
200DMA
4.51
Negative
Market Momentum
MACD
0.21
Negative
RSI
66.08
Neutral
STOCH
74.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RZLT, the sentiment is Positive. The current price of 4.12 is above the 20-day moving average (MA) of 3.17, above the 50-day MA of 3.40, and below the 200-day MA of 4.51, indicating a neutral trend. The MACD of 0.21 indicates Negative momentum. The RSI at 66.08 is Neutral, neither overbought nor oversold. The STOCH value of 74.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RZLT.

Rezolute Risk Analysis

Rezolute disclosed 32 risk factors in its most recent earnings report. Rezolute reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Rezolute Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
$303.36M-0.23%3087.25%97.11%
53
Neutral
$325.29M-74.36%-10.43%
52
Neutral
$5.35B3.83-41.61%2.85%17.10%1.22%
IKIKT
46
Neutral
$167.27M-52.00%-100.00%38.72%
45
Neutral
$170.18M-43.31%95.23%15.55%
42
Neutral
$181.28M-53.27%2.53%
38
Underperform
$163.24M-57.58%15.18%-9.47%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
RZLT
Rezolute
4.12
0.85
25.99%
ACIU
AC Immune SA
1.71
-0.69
-28.75%
DMAC
Diamedica Therapeutics
4.00
0.50
14.29%
FULC
Fulcrum Therapeutics
5.73
-2.02
-26.06%
TNGX
Tango Therapeutics
1.42
-6.47
-82.00%
IKT
Inhibikase Therapeutics
2.09
0.80
62.02%

Rezolute Corporate Events

Private Placements and Financing
Rezolute Closes $96.9 Million Underwritten Offering
Positive
Apr 28, 2025

On April 25, 2025, Rezolute, Inc. announced the closing of its underwritten offering, raising approximately $96.9 million through the sale of 24,940,769 shares of common stock and pre-funded warrants. The funds will be used for research and development, corporate expenses, and working capital. The offering saw participation from new and existing investors and was managed by Guggenheim Securities, with additional support from other financial institutions. Furthermore, a separate private placement is expected to close by May 7, 2025, potentially raising an additional $4.2 million.

Spark’s Take on RZLT Stock

According to Spark, TipRanks’ AI Analyst, RZLT is a Neutral.

Rezolute’s overall stock score is primarily influenced by its challenging financial performance and weak valuation metrics. The company’s strong equity position and recent positive corporate developments provide some optimism, but the overall outlook remains cautious due to persistent losses and operational inefficiencies.

To see Spark’s full report on RZLT stock, click here.

Private Placements and Financing
Rezolute Announces Pricing of Direct Stock Offering
Neutral
Apr 23, 2025

On April 23, 2025, Rezolute, Inc. announced the pricing of a registered direct offering involving the issuance of 20,786,923 shares of common stock and pre-funded warrants to purchase up to 6,905,385 shares, expected to close on April 24, 2025. The offering, managed by Guggenheim Securities, aims to raise approximately $84.2 million, potentially increasing to $96.9 million if additional options are exercised, with proceeds intended for research, development, and general corporate purposes.

Spark’s Take on RZLT Stock

According to Spark, TipRanks’ AI Analyst, RZLT is a Neutral.

Rezolute’s overall stock score reflects significant financial challenges and operational inefficiencies, partially offset by positive corporate developments and strategic improvements. While the stock has potential upside due to recent progress in clinical studies and strategic appointments, its financial health and technical indicators suggest cautious optimism.

To see Spark’s full report on RZLT stock, click here.

Product-Related AnnouncementsBusiness Operations and Strategy
Rezolute Receives Positive DMC Recommendation for Phase 3 Study
Positive
Apr 23, 2025

On April 23, 2025, Rezolute, Inc. announced a positive recommendation from an independent Data Monitoring Committee (DMC) to continue its Phase 3 sunRIZE study without increasing the sample size. This decision supports the company’s initial assumptions about the study’s design and efficacy, with enrollment expected to complete in May 2025 and topline results anticipated by December 2025. The study is evaluating the efficacy and safety of ersodetug in patients with congenital hyperinsulinism, a condition leading to recurrent hypoglycemia. The continuation of the study as planned suggests confidence in ersodetug’s potential as a best-in-class treatment for hyperinsulinism.

Spark’s Take on RZLT Stock

According to Spark, TipRanks’ AI Analyst, RZLT is a Neutral.

Rezolute’s overall stock score reflects significant financial challenges and operational inefficiencies, partially offset by positive corporate developments and strategic improvements. While the stock has potential upside due to recent progress in clinical studies and strategic appointments, its financial health and technical indicators suggest cautious optimism.

To see Spark’s full report on RZLT stock, click here.

Executive/Board ChangesBusiness Operations and Strategy
Rezolute Appoints Erik Harris to Board of Directors
Positive
Mar 28, 2025

Rezolute, Inc. announced the election of Erik Harris to its Board of Directors, effective March 25, 2025. Mr. Harris, deemed independent by Nasdaq standards, brings extensive experience from his roles at Ultragenyx Pharmaceutical Inc. and other life science companies. His appointment is expected to enhance Rezolute’s strategic direction, leveraging his commercial and management expertise. Mr. Harris will receive standard board compensation, including stock options, and his role is anticipated to strengthen the company’s industry positioning.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.